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Abstract
Objective: Quantitative assessment of active bone marrow (BM) in vivo is yet to be well-defined. This study aims to compare 
total body BM volume estimations obtained from use of both18F-FLT PET/CT and 18F-FDG PET/CT in order to consolidate 
higher cellular proliferation rates with imaging the highly active red BM in pancreatic cancer.
Methods: This phase I pilot study includes seven patients with pancreatic cancers who underwent both 18F-FLT and 18F-FDG 
imaging each acquired within a week’s duration. A CT-based classifier is used for segmenting bone into cortical and trabecular 
regions. The total BM volume is determined through statistical thresholding on PET activity found within the trabecular bone.
Results: Results showed that 18F-FLT measures of red BM volume (RBV) were higher than those obtained from 18F-FDG 
(∆=89.21 ml). RBV obtained using 18F-FLT in males were found to have high correlation with measured weight (R2=0.61) and
BMI (R2=0.70). The red BM fraction obtained from 18F-FLT was significantly different between males and females, with 
females showing much higher red bone matter within the trabecular bone (p<0.05). In contrast to 18F-FLT, 18F-FDG BM 
measurements showed that RBV was significantly different between males and females (p<0.05). Results also show that 
spinal activity SUV threshold for red BM segmentation is significantly different between 18F-FLT PET and 18F-FDG PET (p<0.05).
Conclusion: By combining 18F-FLT-PET and 18F-FDG-PET, this study provides useful insights for in vivo BM estimation through 
its proliferative and glycolytic activities.
Key words: PET/CT, 18F-FLT, 18F-FDG, bone marrow imaging, image processing
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Özet
Amaç: In vivo aktif Kemik İliği’nin (Kİ) kantitatif değerlendirmesi tam olarak tanımlanmış değildir. Bu çalışmadaki amaç 
18F-FLT ve 18F FDG görüntüleme yöntemleriyle kemik iliğinin hücresel bölünme aktivitesi ile glikolitik aktivite ile tanımlanan 
hacimlerinin mukayesesini yapmaktır. Bu spesifik çalışmaya esas olan ana çalışma, pancreas kanserli hastalarda başlatılmış bir 
faz 1 araştırmasıdır.
Yöntem: By faz 1 çalışmaya pancreas kanseri olan yedi hasta dahil edilmiştir, bir hafta içerisinde hem 18F-FLT hem 18F-FDG 
görüntülemesi yapılmış, kemik dokusunu kortikal ve trabeküler bölgelere ayırmak için BT bazlı bir sınıflama kullanılmıştır. Total 
Kİ hacmi, trabeküler kemikteki PET aktivitesinin istatiki bir eşikleme metodu uygulanarak belirlenmiştir.
Bulgular: 18F-FLT ile elde edilen kırmızı Kİ hacmi (KKİ) 18F-FDG ile saptanadan daha yüksek bulunmuştur (∆=89,21 ml). 18F-FLT 
ile saptanan KKİ erkeklerde ağırlık (R2=0,61) ve KKİ (R2=0,70) ile yüksek korelasyon göstermektedir. 18F-FLT ile elde edilen 
kırmızı Kİ fraksiyonu erkekler ve kadınlar arasında anlamlı farklılık göstermekteydi, kadınlarda trabeküler kemik içerisinde daha 
yüksek kırmızı kemik maddesi bulunmaktaydı (p<0,05). 18F-FLT’nin aksine 18F-FDG Kİ ölçümleri KKİ’nin kadınlar ve erkekler 
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Introduction
Bone Marrow (BM) is of vital importance in oncological 
applications since it is most sensitive to radiation and 
chemotherapy, and often regarded as the dose-limiting 
factor for systemic radionuclide therapies (1,2,3). Moreover, 
estimating the volume of the highly active red BM is 
essential in stem cell transplantation studies (4), as timely 
stem cell support could improve patient recovery.
Furthermore, clinical studies, which aim to determine 
the correlation between administered dose and sensitivity 
to BM toxicity, can be confounded by potential effects of 
previous treatments.
Despite the advances in the current BM evaluation 
techniques, biopsy remains the gold standard for clinical 
diagnosis of functional and morphologic status (5,6,7). 
However, biopsy that is dependent on site-specific sampling 
often fails to produce a correct estimation of the whole 
body BM distribution due to non- homogeneity within the 
skeletal system.
The International Commission on Radiological 
Protection (ICRP) estimates that total red marrow, which is 
the hematopoietically active tissue is 1.170 g in a healthy 
40-year-old men and 900 g in women, and a total yellow 
marrow of about 2.480 g in men, and 1.800 g in women 
(8,9). Systemic radionuclide therapies mostly affect the red 
BM, and thus, it is of critical importance to estimate its 
volume in individuals undergoing treatment. As estimates 
of BM vary between individuals, patient-specific estimation 
of hematopoietically active red BM would enable better 
characterization of the BM compartment and hence better 
individualized dosimetry (10,11).
Magnetic Resonance Imaging (MRI) based 
techniques that are capable of estimating water and 
fat components of the bone may be able to estimate 
BM volumes (12,13,14). However, the infrequent use 
and long acquisition times of whole-body MRI hamper 
their use for BM estimation applications. More recently, 
quantitative SPECT based techniques using specific 
radiopharmaceuticals have been developed, which target 
the reticuloendothelial system as well as erythropoietic or 
granulopoietic cells for BM estimation (10,15,16). These 
techniques suffer from the limitation due to tracer kinetics 
and the physics of single photon detection in SPECT. 
Recently, a study by Sambuceti et al. estimated the BM 
volume using 2-deoxy-2-(18F)-fluoro-D-glucose (18F-FDG) 
PET/CT. The study that was based on a large population 
is the first of its kind in estimating intraosseous volume 
(IBV) by using SUV measures obtained from glucose 
uptake (17). Since glucose consumption in the IBV is 
indirectly correlated to the glycolytic activity of the BM, the 
distribution of the FDG PET/CT activity serves as a potent 
marker for estimating the red marrow within the skeleton.
Prior to 18F-FLT, developed in the 1990s (18,19), a 
number of markers have been used to predict the biologic 
behavior of tumors and outcome following surgical 
and medical treatments. At a basic histological level, 
mitotic index and lymphovascular invasion are commonly 
used to assess potentially aggressive tumors. Ki-67 is a 
nuclear antigen only present in the nuclei of proliferating 
cells, and good correlation between Ki-67 and S-phase 
indices have been reported by flow cytometry (20). Ki-67 
immunohistochemistry (IHC) has also been used to evaluate 
a tumors’ proliferative activity.
Clinical evaluation and quantification of proliferative 
activity and tumor invasiveness can be performed by using 
FLT-positron emission tomography imaging. Similar to its 
mother drug azidothymidine, 18F-FLT acts as a terminator 
of the growing DNA chain. Actually, only a small amount 
of 18F-FLT is accumulated in DNA; rather, it is retained 
intracellularly after phosphorylation by thymidine kinase 1. 
F-FLT pathway is similar to the imaging of glucose uptake 
pathway with 18F-FDG after trapping by hexokinase. 
Therefore, both compounds reflect accumulation by 
transport and subsequent activation by the first step in 
utilization pathways. 18F-FLT does not reflect the whole 
DNA synthesis, just as 18F-FDG does not reflect the whole 
glucose use. All clinical studies demonstrate a distinct BM 
uptake on 18F-FLT images. Although the exact mechanism is 
still being discussed, red marrow’s precursor cell population 
with high proliferative activity is considered as the main 
reason for 18F-FLT localization.
The primary aim of this study is to estimate the 
distribution of hematopoietic cellular red BM and non-
hematopoietic fibroareolar fatty yellow BM based on a 
combination of 18F-FLT PET and 18F-FDG PET, which both 
target BM compartment and evaluate the glycolytic and 
proliferative properties of BM cells, respectively. In this pilot 
study, a novel technique is proposed to estimate patient 
specific BM volumes based on whole body 18F-FLT PET 
and 18F-FDG PET. The whole bone compartment is first 
separated into cortical bone and trabecular bone by using
arsında anlamlı farklılık gösterdiği saptandı (p<0,05). Sonuçlar kırmızı Kİ segmentasyonu için spinal aktivite SUV eşiğinin 18F-FLT 
PET ile 18F-FDG PET arasında anlamlı derecede farklı olduğunu gösterdi (p<0,05). 
Sonuç: Bu çalışma 18F-FLT-PET ile 18F-FDG-PET’in birleştirilmesinin proliferative ve glikolitik aktivitelerine bağlı olarak in vivo Kİ 
tahminine önemli katkı sağladığını göstermektedir.
Anahtar kelimeler: PET/CT, 18F-FLT, 18F-FDG, kemik iliği görüntülemesi, görüntüleme işlemi
Çıkar Çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemiştir.
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Computed Tomography (CT). The study assumes that 
the BM resides within the trabecular compartment of 
the bone and uses statistical thresholds on PET images to 
estimate the total BM volume within the skeleton. Figure 
1 depicts the general structure of BM estimation method.
Materials and Methods
A. Patient Population and Imaging Protocol 
This investigation was performed on patients who 
underwent 18F-FLT to determine the key imaging 
characteristics of patients with pancreatic cancer. Eligibility 
criteria included age ≥18, ability and willingness to give a 
written consent, life expectancy >3 months, and Karnofsky 
performance status ≥70. Patient demographics for the 
studied population are presented in Table 1.
The patient population did not show presence of visible 
bone metastases on either FDG or FLT PET/CT imaging. In 
addition, Complete Blood Cell (CBC) counts of the subjects 
reported an average glucose level of 117.85 mg/dL, a 
mean RBC count of 4.54x109 cells/ml and a mean platelet 
count of 385.85x109 per ml. The results of the CBC tests 
along with absence of any bone metastases rendered 
the population a viable choice for the study of on BM 
compartment.
The study was performed under an FDA approved 
Investigational New Drug (IND) and after IRB review and 
approval. In this study, 3’-18F-fluoro-3’-deoxy-L- thymidine 
was obtained from Cardinal Health 414, LLC. 18F- FLT 
administered activity was 10±1 mCi, and imaging time 
point was 60±15 minutes post injection, whereas 18F- 
FDG was administered with an activity of 10±1 mCi, and 
imaging time point was 60±15 minutes post injection. 
Images were obtained with 16-slice Siemens PET/CT. The 
scanning parameters for CT imaging were 140 kVp, 80mA, 
0.5s rotation time, and 512×512-pixel matrix.
B. Probabilistic LD A for Cortical and Trabecular 
Bone Segmentation
Linear discriminant analysis (LDA) is a widely used 
technique in pattern recognition, statistics and machine 
learning to determine characteristic features that can 
aid in difficult segmentation tasks (21,22,23,24,25). The 
technique, as used in this study, exploits the fact that 
Hounsfield values are different in cortical and trabecular 
bone on CT images (26). This difference in Hounsfield value 
can be used to train an LDA-based classifier for separating 
the entire bone into cortical and trabecular compartments.
The proposed LDA classifier estimates a posterior 
probability for each voxel of bone compartment on CT 
images (Figure 2A), for segmentation of bone into either 
cortical or trabecular compartments. In order to train the 
classifier, 1000 voxels of CT skeleton in seven patients are 
randomly chosen and manually assigned into one of the 
two groups: Cortical (C) or Trabecular (T).
The training phase estimates the parameters of linear 
discriminant functions for the two classes as given in 
Equation 1.
dCL x,y,z=αC+ βC HVx,y,z, and
dTL x,y,z=αT+ βT HV(x,y,z) (1).
αC, βC, αT, βT are the LDA parameters for the two 
groups cortical (C) and V(x,y,z) represents the Hounsfield 
value of a particular voxel of the CT image. The pprior=0.5, 
suggesting that a given voxel of the skeleton has an equal 
probability of belonging to either one of the two classes.
The segmentation of the entire bone into cortical and 
trabecular requires each pC or pT based on the linear score 
LC and LT, respectively. The posterior probabilities signify 
the likelihood of a voxel to belong to either of the groups. 
The linear scores LC and LT are estimated based on the 
Hounsfield value of the voxel under investigation as given 
by Equation 2.
LC(x,y,z)= dCL x,y,z+log(pprior), and
LTx,y,z= dTL x,y,z+ log(pprior) (2).
The technique computes two 3D posterior probability 
maps for every voxel of the skeleton. A higher posterior 
probability determines the grouping of the voxel.
Following this probabilistic segmentation of the 
skeleton into cortical and trabecular regions, a 3D 
connected islanding algorithm is employed to remove any 
spurious points marked erroneously as trabecular bone. 
The algorithm removes all connected components of the 
trabecular bone that have fewer than P voxels. The study 
uses a 26-point neighborhood connectedness for complete 
Figure 1. General structure of the entire BM estimation approach, showing 
the various steps of the algorithm for BM volume estimation
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3D connectivity of every voxel that touches the faces, 
edges, or corners of the voxel under consideration.
The estimation of the trabecular and cortical bone 
regions is carried out for each patient by CTs co-registered 
to both the 18F-FLT and 18F-FDG PETs. Figure 2B,C shows the 
extracted cortical and trabecular regions of bone by using 
the posterior probability masks generated with Equation 2. 
C. Statistical BM Segmentation 
Estimation of hematopoietically active BM is based 
on the assumption that BM is located in the trabecular 
compartment of bone, and 18F-FLT voxel intensities, as 
seen on PET images, are correlated with the proliferative/
glycolytic activity of the BM. This estimation technique 
extracts only the FLT/FDG activity located in the trabecular 
bone by using the CT-based 3D posterior probability maps 
obtained in the preceding step. Figure 2E shows the 
resultant image obtained by masking the registered FLT-PET 
images with the posterior probability map of the trabecular 
tissue.
Thresholding in PET images has always been a topic 
of great interest, with thresholds playing a critical role 
in determining the correct volume/area of the extracted 
object (27). Various studies with 18F-FLT have shown 
different Standard Uptake Value (SUV) thresholds deemed 
optimal for determining the functionally active BM (28,29). 
In addition, studies have shown that the SUV threshold 
varies for different bones of the body, therefore, no one 
single SUV threshold could possibly be considered as the 
gold standard (28).
To overcome the contentious issue of thresholds, 
a completely statistically driven approach outlined by 
Sambuceti et al. (17) has been adopted for both 18F-FLT 
and 18F-FDG based BM estimation. The approach initially 
estimates the mean (SUV) and standard deviation (SDvert) 
of all the activity located within the trabecular bone, in the 
thoracic and lumbar vertebrae regions as shown in Figure 
2 (D). The technique estimates the red (active) BM volume 
by accounting all voxels of the trabecular bone that are 
above the threshold computed as SUVvert −2.5×SDvert. 
A unique property for estimating the red BM in this study 
is in the use of patient-specific thresholds rather than 
a fixed threshold to account for differences in uptake 
across patients. Less-active yellow BM is estimated as the 
fraction of the trabecular bone volume below the red BM 
threshold. Figure 2F illustrates the resultant image after the 
thresholding operation showing the statistically significant 
voxels of the BM.
D. Volume Estimation 
Cost-effective third party software called ScanIP™ 
developed by Simpleware Ltd. based in the United Kingdom 
is utilized for estimating the volume of the statistically 
significant BM. The calculated volumes are in milliliters 
(ml). Figure 2G shows 3D rendering of BM in the entire 
body with red regions showing red BM and yellow regions 
Figure 2. Full body images at various steps of the BM extraction process 
with the top row showing 18F-FLT and bottom row showing 18F-FDG results. 
(A) CT image (B) Extracted cortical bone using probabilistic LDA (C) Extracted 
trabecular bone following probabilistic LDA (D) Activity in trabecular bone 
in thoracic and lumbar vertebrae regions (E) Activity in trabecular bone in 
the rest of the body excluding thoracic and lumbar vertebrae regions (F) 
Thresholded BM map generated after applying a statistical thresholding on 
PET image. (G) 3D rendering of BM in the entire body, with red regions 
showing red BM and yellow regions corresponding to yellow BM. The 
cortical bone overlay is showing using a transparent white overlay
Table 1. Patient Demographics
Subject Measured 
Weight (kg)
Height (cm) Gender Age at time of 
Imaging (years)
Ideal Body Weight 
(kg)
Body Mass Index 
(BMI) (kg/m2)
1 61.68 157 F 65 52.38 24.87
2 138.79 180 M 54 72.89 42.68
3 104.32 185 M 53 76.70 30.34
4 68.49 180 M 59 72.89 21.06
5 63.04 165 M 68 61.50 23.13
6 68.94 183 M 63 74.79 20.61
7 70.76 160 F 59 54.11 27.66
Average 82.29±28.79 172.85±11.76 60.14±5.55 146.54±2.62 27.19±7.66
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showing corresponding yellow BM. The cortical bone is 
shown using a transparent white overlay.
E. Statistical Analysis 
All results are presented in the form of mean ± standard 
deviation. Linear regressions as performed in this study 
make use of the least square technique and report the R2 
of the fit and the p-value. All comparative results between 
18F-FLT and 18F-FDG based estimations are carried out 
through paired t-tests. A p-value of <0.05 is considered 
statistically significant.
F. Ethics Statement 
The research has been approved by the Western 
Institutional Review Board. A Certificate of approval from 
the WIRB has been obtained. Each participant provided 
a written consent to participate in the study as per the 
requirements and guidelines of the IRB.
Results
G. Probabilistic LD A Segmentation 
To assess the results of the Probabilistic LDA used for 
segmenting the bone into cortical and trabecular regions, 
the leave-one-out cross-validation (LOOCV), which is a 
trusted model for assessing the performance of classifiers, 
is used in this study. The classification experiment was 
implemented 50 times on 50 random training sets of 
1000 samples. Table 2 provides the average training and 
LOOCV testing metrics (accuracy, sensitivity, specificity and 
precision) of the classification results performed across all 
the 14 CT scans (seven co-registered to 18F-FLT and seven 
co-registered to 18F-FDG).
H. Whole Body BM Volumetric Assessment
Estimated BM volumes for the study patients are 
illustrated in Tables 3 and 4 using 18F-FLT and 18F-FDG, 
respectively, showing the average red and yellow BM 
volumes for each patient with the standard deviation 
obtained upon executing the algorithm 50 times. The tables 
also provide the volumes of the trabecular bone region 
along with the fraction of red BM within the trabecular 
region.
In addition, it is seen that the estimates of Trabecular 
Bone Volume (IBV) from the CT images co-registered to 
either FLT or FDG PET/CT were not significantly different 
(p=0.49). Additionally, it is seen that 18F-FLT based 
measures of red BM volume (RBV) were higher than those 
obtained by 18F-FDG (∆=89.21 ml), but results of a paired 
t-test demonstrate that they were not significantly different 
(p=0.55). Consecutively, estimated total body yellow BM 
volume (YBV) from the two different tracers namely 18F-FLT 
and 18F-FDG were not significantly different (p=0.112). 
The red BM fraction estimated from 18F-FLT was higher 
Figure 3. Influence of (A) Measured Body Weight, and (B) Body Mass 
Index (BMI) on Red BM Volume (RBV) obtained from 18F-FLT imaging in all 
subjects, whereas (C) and (D) show the influence of measured body weight 
and BMI in only males, respectively. The RBVs showed better correlation to 
physical measurements when female subjects were excluded
Table 2. Classification performance
Accuracy Sensitivity Specificity Precision
Training 0.94±0.04 0.96±0.02 0.91±0.04 0.92±0.05
LOOCV 0.92±0.04 0.93±0.03 0.90±0.07 0.91±0.04
Table 3. Estimated Whole Body BM volumes using 18F-FLT PET/CT imaging
Patient Gender
Marrow Volumes
Trabecular Bone Volume (IBV)
Red BM Fraction
88 (RBV/IBV)Red (RBV) Yellow (YBV)
1 F 1136.37±17.7 513.63±22.87 1650±22.67 0.69
2 M 421.16±26.94 598.84±16.11 1020±23.27 0.41
3 M 799.73±12.61 820.27±18.8 1620±16.21 0.49
4 M 697.94±33.64 682.06±22.7 1380±28.44 0.51
5 M 778.07±28.53 551.93±18.83 1330±24.76 0.59
6 M 849.31±21.7 640.69±11.64 1490±19.54 0.57
7 F 486.52±29.63 143.48±23.35 630±25.67 0.77
Average 738.44±220.95 564.42±195.19 1302.86±337.12 0.58±0.11
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than that estimated from 18F-FDG but was not statistically 
different for the 7 patients in the study. (∆=0.08; p=0.25).
I. Effects of Weight, Height, and BMI on Whole 
Body BM Volumes 
For 18F-FLT based BM measurements it is seen that 
although the RBV was not affected by gender (p=0.653), 
the YBV was significantly different between males and 
the females (p<0.05). Also, the RBV did not show a good 
correlation with the measured weight (R2=0.32; Figure 3A), 
measured height (R2=0.06), Body Mass Index (R2=0.34; 
Figure 3B) and ideal body weight (R2=0.05). Similar trends 
were seen for YBV and IBV for the subjects in this study. 
However, on the exclusion of female subjects (n=2) from 
regression analysis, it is observed that a higher correlation 
was obtained for RBV with measured weight (R2=0.61; 
Figure 3C) and the BMI (R2=0.70; Figure 3D).
Finally, the red BM fraction was found to be loosely 
correlated with the measured weight (R2=0.49; Figure 4A) 
and well correlated to the measured height (R2=0.68) and 
the ideal body weight (R2=0.73; Figure 4B). It was also 
significantly different between males and females, with 
females showing much higher red bone matter within 
trabecular bone (p<0.05).
For 18F-FDG based BM measurements, it was seen that 
RBV was significantly different between males and females 
(p<0.05), however YBV and IBV were not statistically 
different between the two genders. Also for 18F-FDG, RBV 
did not correlate well with measured weight (R2=0.24), 
and Body Mass Index (R2=0.08) and correlated weakly 
with measured height (R2=0.43) and ideal body weight 
(R2=0.47).
An interesting feature is seen among males in the 
study population, where stronger correlation of the IBV 
with measured weight (R2=0.77), and BMI (R2=0.61) were 
observed. Also, red BM fraction was not strongly correlated 
to any demographic features when measured using 18F-FDG 
PET/CT (Figure 4C and 4D).
J. SUV Assessment 
The SUV measure of 18F-FLT images is an indicator of 
the proliferative activity of BM, whereas the SUV measure 
in 18F-FDG imaging is indicative of the glycolytic activity 
of the BM compartment. Table 5 shows the mean SUV 
values corresponding to the spinal column and the rest 
of the body (ROB). Results show that the spinal activity 
SUV that is used to determine the threshold for red BM 
segmentation was significantly different between 18F-FLT 
PET and 18F-FDG PET (p<0.05). Also, the SUV for the rest 
of the body (excluding the skull) was found to be different 
between the two imaging tracers. Moreover, the results 
of an ANOVA for both FDG and FLT based BM estimation 
suggest that the mean spinal and rest-of-body SUVs were 
not different among males and females.
In addition, as seen in Figure 5, red BM volumes were 
not very well correlated to the mean spinal SUVs for 18F-FLT 
(R2=0.13; Figure 5A), but were comparatively better 
correlated in the case of 18F-FDG (R2=0.71; Figure 5C). 
Also, the yellow BM volumes were not very well correlated 
with the mean SUVs of the rest of the body for both FLT- 
and FDG-based estimations (Figure 5B and 5D).
An important finding is that the SUV values in the 
spine and rest of the body vary significantly for different 
subjects. This variation is an important aspect that needs to 
be considered when 18F-FLT images are thresholded using 
fixed SUV values. This variation in the different statistically 
Figure 4. Correlation between Red BM Fraction and (A) Measured Weight 
and (B) Ideal Body Weight using 18F-FLT PET imaging. Parts (C) and (D) show 
the same correlation on 18F-FDG PET. A higher correlation was detected 
between RBV and measured weight and ideal body weight in 18F-FLT based 
RBV estimations as compared to 18F-FDG imaging
Figure 5. Correlation between (A) Red BM Volume (RBV) to mean spinal 
SUV and (B) Yellow BM Volume (YBV) to mean rest of body SUV for 18F-FLT 
imaging. Parts (C) and (D) show the same result for 18F-FDG imaging. RBV 
are well-correlated for 18F-FDG but not for 18F-FLT imaging
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meaningful SUV thresholds combined with the fact that the 
mean SUV value in the trabecular bone varies significantly 
from patient to patient, suggests that the use of statistical 
thresholds, like the one suggested in this article, may be 
advantageous for obtaining more meaningful results.
Discussion
To the best of our knowledge of the literature, this study 
is the first to compare total body BM volume estimations 
obtained from the use of 18F-FLT PET/CT and 18F-FDG 
PET/CT. The study presented an augmented approach for 
eliciting a better understanding of the BM compartment 
by combining the glycolytic activity of 18F-FDG PET and 
proliferative activity of 18F-FLT PET, each being acquired 
within a week’s duration for the same patient. Other 
studies using 18F-FLT for imaging the BM compartment 
have focused on particular regions of interest rather than 
providing a measure of the total active BM in the human 
body (28,30). Also, the nature of the proposed technique 
renders it possible to extract and quantify the active BM 
within any bone in the body.
An important contribution relates to the use of the 
probabilistic LDA technique for extracting compact and 
trabecular bone compartments. This probabilistic technique 
is based on the assumption that compact bone in CT 
images appears as having the highest Hounsfield value and 
that trabecular bone located in its cavity has a significantly 
lower Hounsfield value (11,26). This assumption along with 
the probabilistic training approach enables the technique to 
be applied on every single slice of the CT image without 
any human intervention, once the classifier is trained.
Also, as seen in the results, the IBV estimations are 
not significantly different between those estimated from 
CTs co-registered to 18F-FLT and 18F-FDG PETs. This finding 
is expected in such studies since the discrepancies in 
measurements of the IBV can result in incorrect estimations 
of BM volumes. Also, since the imaging of FLT and FDG 
PET/CT is not performed more than a week apart, no 
expected discrepancies should be observed in the CT-based 
bone volume measurements as seen in the results. The 
insignificant differences may be due to the probabilistic 
nature of the segmentation algorithm for delineating 
cortical from trabecular bone.
Moreover, the probabilistic LDA based technique classifies 
the brain as trabecular bone as can be seen in Figure 2C, 
but it is not a major source of error in BM estimation due to 
the targeted uptake of 18F-FLT. Brain tissue does not show 
significant uptake of 18F- FLT, as in the case of FDG, which 
is the primary reason why the skull needs to be omitted 
from the quantification purposes. The use of 18F-FLT offers 
a unique opportunity to quantify the BM volume (albeit 
negligible) in the skull, which is not estimated in studies 
based on FDG. It is seen in this study that indeed negligible 
BM is found in the skull, which is conform to the proposed 
BM distribution, as was also confirmed in other studies 
Table 5. SUV measures
PET Tracer Overall Male Female p-value (Male vs. Female)
18F-FDG
Spinal 1.74±0.26 1.83±0.25 1.51±0.04 0.152
ROB 0.69±0.29 0.75±0.33 0.54±0.06 0.438
18F-FLT
Spinal 2.92±0.44 3.05±0.44 2.56±0.29 0.245
ROB 1.00±0.13 0.96±0.14 1.09±0.02 0.265
p-value (FDG vs. FLT)
Spinal < 0.05
ROB < 0.05
Table 4. Estimated Whole Body BM volumes using 18F-FDG PET/CT imaging
Patient Gender
Marrow Volumes
Trabecular Bone Volume (IBV) Red BM Fraction (RBV/IBV)Red (RBV) Yellow (YBV)
1 F 405.2±21.49 1155±24.93 1560.2±19.01 0.25
2 M 922.2±15.63 728.3±18.22 1650.5±21.63 0.55
3 M 625.6±17.97 965±18.38 1590.6±19.72 0.39
4 M 537.9±22.69 833.1±26.1 1371±16.45 0.39
5 M 723.4±19.76 597±21.94 1320.5±18.24 0.54
6 M 937±22.81 573.1±21.53 1510.1±21.72 0.62
7 F 393.4±17.93 214.6±18.94 608±18.59 0.64
Average 649.23±207.30 723.75±281.35 1372.98±330.85 0.49±0.13
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(17,28). The quantitative measurement of the total active 
BM volume in the body has not been clearly defined in the 
literature. The primary description of the BM compartment 
and its related measures come from the 1926 study by 
Mechanik and its various reviews by Woodward and 
Holodny, Cristy and Ellis (31,32,33,34).
Mechanik’s study that is based on 13 subjects who died 
of non-hematological diseases is the fundamental study on 
which all BM estimates are based (33). A recent study by 
Sambuceti et al. estimated the BM volume using FDG PET/
CT. This study that was based on a large population was 
first of its kind to estimate intraosseous volume (IBV) using 
SUV measures obtained from glucose uptake (17).
This study showed that 18F-FLT based BM estimations 
were higher than those obtained from 18F-FDG PET 
imaging, all but for two patients. The differences between 
the BM estimations for the two imaging modalities may be 
a result of the difference in the distribution and mechanism 
of the PET tracer within the body.
18F-FLT enables us to visualize the true hematopoietically 
active BM compartment of the body in order to estimate 
the whole body volume. Additionally, the assessment of the 
RBV was very close to the one obtained by Sambuceti et 
al., which showed that the mean RBV was approximately 
541±195 ml.
The measured BM volumes in this study are slightly 
lower than those reported from other studies, which are 
based on cadaver studies. There are various reasons that 
could account for such differences. The difference in values 
from the Mechanik data can be explained due to the 
different methods used. Mechanik employed prolonged 
boiling of the bone in a post-mortem analysis whereas the 
presented technique involves metabolic imaging.
This study also showed that the RBV volumes estimated 
by FLT were not significantly different between males and 
females as was the case using FDG. Other studies based on 
FDG have showed that assessments of BM were significantly 
different between the two genders as was confirmed here 
in this study (17). Also, we found that the mean SUVs of 
the spinal region and the rest of the body were significantly 
different between FLT- and FDG-based imaging. The higher 
mean SUV when using FLT signifies that FLT is a better 
targeting agent for BM estimation as compared to FDG. Also, 
the ratio of the mean spinal activity SUV to the mean SUV 
of the rest of body is higher in FLT imaging (2.92 vs. 2.52 for 
FDG), which may provide a higher contrast in estimating red 
BM and hence an improved estimation of RBV.
Although the proposed approach of this study is based 
on finding statistically meaningful BM volumes, it does 
have some intrinsic limitations. The primary limiting factor 
is the effect of partial volume averaging, which is observed 
both in CT and PET images (35). This may often lead to 
an overestimation of the cortical and trabecular regions 
and in turn the BM volumes. Also, motion artifacts due 
to the long imaging time of the PET as compared to CT 
is another potential source of estimation error (36). The 
probabilistic LDA technique has a cross-validated accuracy 
of 91%, which may be attributed to errors in estimating 
the boundary between the cortical and trabecular bone 
regions, which in turn could lead to errors in BM volume 
measurements. Finally, the size of the population of this 
pilot study is a primary limitation and current findings 
are needed to be verified through the inclusion of more 
subjects as they become available, and as we continue to 
augment our understanding of pancreatic cancer in order 
to offer better and more effective means for diagnosis and 
ultimately better treatment. The small number of patients 
included in this pilot study is dictated primarily by the 
nature of the disease which observes the lack of simple 
early detection methods and the earliest indications of 
disease being nonspecific. Also, the intensive nature of the 
imaging task with both 18F-FLT and 18F-FDG PET/CT may 
have been a limiting factor for inclusion of subjects.
Although some limitations exist, the study provides a 
unique quantitative assessment of the whole-bone marrow 
compartment using its proliferative and glycolytic activity in 
the same patients to provide new insights in the distribution 
of the active bone marrow for various applications.
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